Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
Daniela Paola Roggeri, Alessandro Roggeri ProCure Solutions, Nembro, Bergamo, Italy Purpose: Hepatic encephalopathy (HE) is associated with a reduced survival, an increased risk of hospitalization for recurrences, and a reduced health-related quality of life. The purpose of the present econ...
Guardado en:
Autores principales: | Roggeri DP, Roggeri A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0221b76cd3d14738b2da70f91fdfe6d1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
por: Roggeri DP, et al.
Publicado: (2015) -
Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia MD, et al.
Publicado: (2011) -
Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?
por: Kornerup LS, et al.
Publicado: (2019) -
Hepatic encephalopathy: current challenges and future prospects
por: Swaminathan M, et al.
Publicado: (2018) -
Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options
por: Philips CA, et al.
Publicado: (2019)